The previous page is sending you to http://www.b3cnewswire.com/201701051515/xigens-brimapitide-an-innovative-jnk-inhibitor-delivers-positive-phase-ii-results-in-inflammatory-eye-disease.html.

 If you do not want to visit that page, you can return to the previous page.